The first stop for professional medicines advice

Guidance

625 results

Applied filters

Patient Group Direction use in End of Life Care

10 August 2020Considerations required before implementing Patient Group Directions (PGDs) in End of Life Care.

National Homecare Medicines Committee (NHMC) Engagement with Manufacturers Advice

4 August 2020The National Pharmaceutical Supply Group (NPSG) currently advises against participation in advisory boards sponsored by Manufacturers (Marketing Authorisation Holders). This NHMC paper supports this advice…

National Homecare Medicines Committee (NHMC) Homecare Digital Strategy

4 August 2020This is the NHMC and NCHA joint digital strategy and roadmap for the next 5 years. It sets out a direction of travel for homecare…

Tissue Engineered Products - Pharmacy Institutional Readiness Guidance

21 July 2020This document outlines key areas for focus of pharmaceutical expertise prior to an organisation implementing Tissue Engineered Products.

PGD use in services provided by multiple organisations

14 July 2020Principles to be considered are outlined for Patient Group Directions used in the provision of medicines/vaccines in services provided by multiple organisations

Patient Specific Directions (PSD)

10 June 2020This article describes Patient Specific Directions and the requirements for their writing and use

Bank and agency staff and Patient Group Directions

25 February 2020The below summarises the advice on the use of PGDs by bank and agency staff working within organisations.

Out of Specification Advanced Therapy Medicinal Products - Guidance for Healthcare Organisations

24 February 2020This document clarifies the regulatory expectation regarding OOS ATMPs and advises hospitals on Governance in the event of an OOS ATMPs being offered for use.

Pharmacy Oversight and Supervision Requirements for Preparation of Licensed ATMPs

31 January 2020This guidance provides definitions of oversight and supervision it clarifies where each are required when implementing ATMPs.

Off-label or unlicensed product use under HMR 2012 exemptions

8 January 2020A legal position summary regarding the sale, supply or administration of off-label/unlicensed products under Schedule 17 of the Human Medicines Regulations 2012